State of Alaska Department of Revenue boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,999 shares of the medical instruments supplier’s stock after buying an additional 1,819 shares during the period. State of Alaska Department of Revenue’s holdings in Becton, Dickinson and were worth $6,438,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BDX. Guardian Life Insurance Co. of America raised its position in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 6 shares during the last quarter. Wellington Shields & Co. LLC raised its position in Becton, Dickinson and by 0.3% in the first quarter. Wellington Shields & Co. LLC now owns 2,534 shares of the medical instruments supplier’s stock valued at $465,000 after buying an additional 8 shares during the last quarter. Parkside Financial Bank & Trust raised its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the last quarter. Northstar Group Inc. raised its position in Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after buying an additional 9 shares during the last quarter. Finally, North Star Investment Management Corp. raised its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the last quarter. Institutional investors own 87.41% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) traded down 0.56% during midday trading on Wednesday, hitting $197.78. 293,372 shares of the company’s stock were exchanged. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock’s 50 day moving average is $200.05 and its 200-day moving average is $189.42. The stock has a market cap of $45.01 billion, a PE ratio of 57.28 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same period in the prior year, the business earned $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. Analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be given a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is 83.43%.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-position-increased-by-state-of-alaska-department-of-revenue/1532289.html.

Several equities analysts have weighed in on the stock. Barclays PLC reiterated an “equal weight” rating and issued a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $195.79.

In other news, insider Gary M. Cohen sold 15,044 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the completion of the sale, the insider now directly owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total value of $941,253.60. Following the completion of the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders sold 48,605 shares of company stock valued at $9,718,986 over the last three months. 1.40% of the stock is owned by company insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.